Log In
Preferred Infliximab Products for Treatment of Autoimmune Disorders Update
As of January 01, 2023, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will update its infliximab utilization criteria to prefer Avsola™ and Inflectra®. Remicade® will be removed from preferred status.
To ensure a smooth transition, patients with a current Remicade prior authorization approval may transition to one of the preferred agents (Avsola or Inflectra) on 1/1/23 without requirement of an additional prior authorization at that time. Initial Avsola and Inflectra prior authorizations will be active through the original Remicade prior authorization approval date. An additional prior authorization will be required after 1/1/23 to continue Remicade therapy.
Requests for continuation of Remicade will not be able to be reviewed until after 1/1/23. Please submit all requests via the CMM Portal for fastest processing times.
Learn more about Infliximab (Remicade® ) and Infliximab Biosimilars (PDF).
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.